|
|
|
|
|
by Terr_
782 days ago
|
|
P.S. IANAPhlebotomist, but if I could wave a wand to change the nomenclature, I'd make it stop relying on an implicit "nothing" state that keeps changing under us as we discover new features that are either usually-present or usually-absent. Instead patients would have a "blood code" that indicates the tested presence or absence of phenotype cellular features, and any feature not listed would be considered "not yet known, do a test if it might be important." For example, today's AB- would become +HAB-R for "has H,A,B lacks Rhesus factor." Similarly, O+ would become +HR-AB, and the super rare mutation we were just talking about would be either +R-HAB or -HABR. Then when we eventually discover a yet-another factor X... Well, yes, your code wouldn't be constant throughout your life, because after an X-test it would gain either a +X or -X... However the upshot is that it eliminates weird implicit guessing games, and medical professionals will "know what they don't know". |
|
That's already the way A, B, and Rhesus factor work. The abbreviation for Rhesus factor is "+", but the formal terminology is "Rh+". I would have expected "H-" by analogy.